Literature DB >> 35290436

RNA Helicase DHX37 Facilitates Liver Cancer Progression by Cooperating with PLRG1 to Drive Superenhancer-Mediated Transcription of Cyclin D1.

Zhen Liu1, Youqiong Ye2, Yizhe Liu1, Yanfang Liu1, Huifang Chen2, Mengting Shen1, Zhen Wang1, Shenglin Huang1,3, Leng Han4, Zhiao Chen1, Xianghuo He1,3.   

Abstract

RNA helicases are dysregulated in tumors. Here, we identified DHX37 as one of the top RNA helicase genes with upregulated expression in hepatocellular carcinoma (HCC). DHX37 promoted proliferation of liver cancer cells in vitro and in vivo. Epigenomic profiling of DHX37-knockdown and control HCC cells revealed that DHX37 is associated with superenhancer activity. Mechanistically, DHX37 interacted with pleiotropic regulator 1 (PLRG1) to transcriptionally activate cyclin D1 (CCND1) expression via co-occupation of its promoter and superenhancer elements. DHX37 and PLRG1 promoted liver cancer cell proliferation and contributed to the poor prognosis of patients with HCC. Importantly, CCND1 inhibitors were effective as antiproliferative agents for liver cancer. These results together demonstrate a cooperative mechanistic interaction between DHX37 and PLRG1 that regulates CCND1 expression and promotes liver cancer progression, advancing our understanding of the epigenetic and transcriptional dysregulations mediated by RNA helicases and superenhancers in HCC. SIGNIFICANCE: This work characterizes a novel mechanism of superenhancer-driven cyclin D1 upregulation by DHX37 and PLRG1, implicating this pathway as a potential therapeutic target in hepatocellular carcinoma. ©2022 The Authors; Published by the American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35290436     DOI: 10.1158/0008-5472.CAN-21-3038

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   13.312


  2 in total

1.  DDTC Suppresses Ovarian Cancer Development via the PI3K/AKT/mTOR Signaling Pathway.

Authors:  Meng Li; Wenqi Zhang; Yihan Wang; Kai Huang; Tao Sun; Zhicong Qiu; Linqi Yang; Meng Wu; Xiaolu Zhang; Wei Zhang
Journal:  Dis Markers       Date:  2022-08-08       Impact factor: 3.464

2.  Development of Olaparib-Resistance Prostate Cancer Cell Lines to Identify Mechanisms Associated with Acquired Resistance.

Authors:  Maxime Cahuzac; Benjamin Péant; Anne-Marie Mes-Masson; Fred Saad
Journal:  Cancers (Basel)       Date:  2022-08-11       Impact factor: 6.575

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.